Cargando…

Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population

BACKGROUND: Medication satisfaction is a patient-reported outcome which could show medication adherence. The aim of this study was to determine Iranian MS patients’ satisfaction with Disease Modifying Therapies (DMTs). METHODS: A standardized questionnaire was developed using Treatment Satisfaction...

Descripción completa

Detalles Bibliográficos
Autores principales:	Molazadeh, Negar, Sahraian, Mohammad Ali, Ghajarzadeh, Mahsa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Babol University of Medical Sciences 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9878908/ https://www.ncbi.nlm.nih.gov/pubmed/36741493 http://dx.doi.org/10.22088/cjim.14.1.89

Ejemplares similares

Predictors of Catching COVID-19 Infection during Pandemic Stage in Patients with Multiple Sclerosis (MS)
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2022)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports
por: Rastkar, Mohsen, et al.
Publicado: (2023)

Relationship between Sleep Quality and Quality of Life in Patients with Multiple Sclerosis
por: Sarraf, Payam, et al.
Publicado: (2014)

The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): A systematic review and meta-analysis
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2021)

The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis
por: Moghadasi, Abdorreza Naser, et al.
Publicado: (2021)

Age at menarche and risk of multiple sclerosis (MS): a systematic review and meta-analysis
por: Azimi, Amirreza, et al.
Publicado: (2019)

Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran
por: Sahraian, Mohammad Ali, et al.
Publicado: (2020)

Pregnancy History, Oral Contraceptive Pills Consumption (OCPs), and Risk of Multiple Sclerosis: A Systematic Review and Meta-Analysis
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2022)

Predictors of suicidal ideation among Iranian patients with multiple sclerosis
por: Asgarian, Fatemeh Sadat, et al.
Publicado: (2020)

Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis
por: Baghbanian, Seyed Mohammad, et al.
Publicado: (2018)

The relationship between retinal layer thickness and cognition in patients with multiple sclerosis: A systematic review of current literature
por: Moghadasi, Abdorreza Naser, et al.
Publicado: (2023)

Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis
por: Ayati, Nayyereh, et al.
Publicado: (2021)

Emotional Intelligence (EI) of Patients with Multiple Sclerosis (MS)
por: GHAJARZADEH, Mahsa, et al.
Publicado: (2014)

The Effect of Vitamin D Supplements on Clinical and Para-Clinical Outcomes in Patients With Multiple Sclerosis: Protocol for a Systematic Review
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2019)

Prevalence of Multiple Sclerosis (MS) in Zanjan Province of Iran
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2020)

Effect of Vitamin D Supplements on Relapse Rate and Expanded Disability Status Scale (EDSS) in Multiple Sclerosis (MS): A Systematic Review and Meta-Analysis
por: Hanaei, Sara, et al.
Publicado: (2021)

COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis
por: Abbasi, Naghmeh, et al.
Publicado: (2022)

Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis
por: Sahraian, Mohammad Ali, et al.
Publicado: (2020)

The perspective of Iranian patients with multiple sclerosis on the third dose of COVID-19 vaccine
por: Ghadiri, Fereshteh, et al.
Publicado: (2022)

Comparison of serum vitamin D level in multiple sclerosis patients, their siblings, and healthy controls
por: Eskandari, Ghazaleh, et al.
Publicado: (2015)

Level of attitude toward complementary and alternative medicine among Iranian patients with multiple sclerosis
por: Harirchian, Mohammad Hossein, et al.
Publicado: (2014)

Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection?
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2020)

Iranian specialists’ approach to surgery in patients with multiple sclerosis
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Characteristics of COVID-19 disease in multiple sclerosis patients
por: Barzegar, Mahdi, et al.
Publicado: (2020)

Validity and Reliability of the Persian Version of the PERception de la Scle’rose En Plaques et de ses Pousse’es Questionnaire Evaluating Multiple Sclerosis-related Quality of Life
por: Ghajarzadeh, Mahsa, et al.
Publicado: (2016)

Vitamin D and multiple sclerosis
por: Harandi, Asghar Amini, et al.
Publicado: (2014)

Seizure in Iranian patients with multiple sclerosis
por: Zare, Mohammad, et al.
Publicado: (2013)

Iranian consensus on use of vitamin D in patients with multiple sclerosis
por: Jahromi, Soodeh Razeghi, et al.
Publicado: (2016)

Evaluating the relationship between emotional intelligence and cognitive disorders in patients with Multiple Sclerosis
por: Owji, Mahsa, et al.
Publicado: (2018)

Association of AIRE Polymorphism and the Susceptibility to Multiple Sclerosis in Iranian Population
por: Sadeghian-Rizi, Tahereh, et al.
Publicado: (2018)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Disease‐modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta‐analysis
por: Valizadeh, Amir, et al.
Publicado: (2022)

The effect of body mass index on the morbidity and outcomes of COVID-19 in Iranian patients with multiple sclerosis
por: Rezaeimanesh, Nasim, et al.
Publicado: (2023)

Is Body Mass Index (BMI) Associated with Risk and Outcomes of COVID-19 in Iranian Multiple Sclerosis Patients?
por: Rezaeimanesh, Nasim, et al.
Publicado: (2023)

The prevalence of multiple sclerosis in Tehran, Iran, in 2020
por: Eskandarieh, Sharareh, et al.
Publicado: (2023)

Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV
por: Ali Sahraian, Mohammad, et al.
Publicado: (2021)

Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection
por: Maghbooli, Zhila, et al.
Publicado: (2022)

Fear of re-infection, relapse, and anxiety during COVID-19 pandemic in patients with multiple sclerosis: A multi-center study
por: Moghadasi, Abdorreza Naser, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_krhgeehp4p11ptlrsa29e2opgq